222 related articles for article (PubMed ID: 30449862)
1. [Seven Cases of Metastatic Colorectal Cancer Treated with Dose-Reduced and Duration-Reduced Regorafenib Treatment].
Nakashima M; Fujiwara H; Nakao E; Maebashi M; Sugimasa N; Kakizoe M; Ono H; Sugita M
Gan To Kagaku Ryoho; 2018 Nov; 45(11):1673-1676. PubMed ID: 30449862
[TBL] [Abstract][Full Text] [Related]
2. [Tolerability and efficacy of regorafenib in patients with unresectable metastatic colorectal cancer].
Tanaka A; Sadahiro S; Suzuki T; Okada K; Saito G
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1231-6. PubMed ID: 25335705
[TBL] [Abstract][Full Text] [Related]
3. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
Van Cutsem E; Martinelli E; Cascinu S; Sobrero A; Banzi M; Seitz JF; Barone C; Ychou M; Peeters M; Brenner B; Hofheinz RD; Maiello E; André T; Spallanzani A; Garcia-Carbonero R; Arriaga YE; Verma U; Grothey A; Kappeler C; Miriyala A; Kalmus J; Falcone A; Zaniboni A
Oncologist; 2019 Feb; 24(2):185-192. PubMed ID: 30190299
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
[TBL] [Abstract][Full Text] [Related]
5. The real-world use of regorafenib for metastatic colorectal cancer: multicentre analysis of treatment pattern and outcomes in Hong Kong.
Lam KO; Lee KC; Chiu J; Lee VH; Leung R; Choy TS; Yau T
Postgrad Med J; 2017 Jul; 93(1101):395-400. PubMed ID: 27836933
[TBL] [Abstract][Full Text] [Related]
6. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
[TBL] [Abstract][Full Text] [Related]
7. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
Adenis A; de la Fouchardiere C; Paule B; Burtin P; Tougeron D; Wallet J; Dourthe LM; Etienne PL; Mineur L; Clisant S; Phelip JM; Kramar A; Andre T
BMC Cancer; 2016 Jul; 16():412. PubMed ID: 27389564
[TBL] [Abstract][Full Text] [Related]
8. Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting.
Yamaguchi K; Komatsu Y; Satoh T; Uetake H; Yoshino T; Nishida T; Yamazaki N; Takikawa H; Morimoto T; Chosa M; Sunaya T; Hamada Y; Muro K; Sugihara K
Oncologist; 2019 Jul; 24(7):e450-e457. PubMed ID: 30606885
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
[TBL] [Abstract][Full Text] [Related]
10. [Investigation of Administration Technique of Regorafenib in Our Center].
Matsuda C; Danno K; Miyazaki S; Fujitani K; Kubota M; Motoori M; Nakatsuka R; Nishimura M; Kitagawa A; Takagi M; Iwase K
Gan To Kagaku Ryoho; 2017 Jan; 44(1):47-51. PubMed ID: 28174379
[TBL] [Abstract][Full Text] [Related]
11. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
Köstek O; Hacıoğlu MB; Sakin A; Demir T; Sarı M; Ozkul O; Araz M; Doğan AF; Demircan NC; Uzunoğlu S; Çiçin İ; Erdoğan B
Cancer Chemother Pharmacol; 2019 Jan; 83(1):115-122. PubMed ID: 30374523
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Standard Initial Dose and Reduced Initial Dose Regorafenib for Colorectal Cancer Patients: A Retrospective Cohort Study.
Nakashima M; Ide K; Kawakami K
Target Oncol; 2019 Jun; 14(3):295-306. PubMed ID: 31093834
[TBL] [Abstract][Full Text] [Related]
13. Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report.
Yoshino K; Manaka D; Kudo R; Kanai S; Mitsuoka E; Kanto S; Hamasu S; Konishi S; Nishitai R
J Med Case Rep; 2017 Aug; 11(1):227. PubMed ID: 28818109
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
Sueda T; Sakai D; Kudo T; Sugiura T; Takahashi H; Haraguchi N; Nishimura J; Hata T; Hayashi T; Mizushima T; Doki Y; Mori M; Satoh T
Anticancer Res; 2016 Aug; 36(8):4299-306. PubMed ID: 27466548
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F
Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review.
Røed Skårderud M; Polk A; Kjeldgaard Vistisen K; Larsen FO; Nielsen DL
Cancer Treat Rev; 2018 Jan; 62():61-73. PubMed ID: 29175677
[TBL] [Abstract][Full Text] [Related]
17. Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study.
Ozaki Y; Shindoh J; Gonoi W; Nishioka Y; Kondoh C; Tanabe Y; Matoba S; Kuroyanagi H; Hashimoto M; Takano T
BMC Cancer; 2018 Feb; 18(1):138. PubMed ID: 29402244
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy.
Marks EI; Tan C; Zhang J; Zhou L; Yang Z; Scicchitano A; El-Deiry WS
Cancer Biol Ther; 2015; 16(12):1710-9. PubMed ID: 26561209
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib: A Review in Metastatic Colorectal Cancer.
Dhillon S
Drugs; 2018 Jul; 78(11):1133-1144. PubMed ID: 29943375
[TBL] [Abstract][Full Text] [Related]
20. Regorafenib therapy in metastatic colorectal cancer patients: markers and outcome in an actual clinical setting.
Unseld M; Filip M; Seirl S; Gleiss A; Bianconi D; Kieler M; Demyanets S; Scheithauer W; Zielinski C; Prager G
Neoplasma; 2018; 65(4):599-603. PubMed ID: 29940763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
